Spravato (Nasal Esketamine) is an FDA-approved nasal spray formulation for treatment-resistant depression, that patients self-administer under supervision in a clinical setting. It is used in conjunction with an oral antidepressant, and typically involves multiple sprays over a session, with specific dosages based on the treatment protocol.

All insurance carriers in New Jersey (including Medicare and Medicaid) have a policy to cover both TMS and Spravato. A big benefit of our practice is that TMS and Spravato are our specialty, so we are adept at handling the insurance process from inquiry to completion. We ensure that insurance-related questions are addressed and thoroughly discussed before starting any treatment.

Yes, both TMS and Spravato are FDA-approved treatments for the indication of treatment-resistant depression – meaning both treatments have undergone rigorous testing for safety and efficacy in these contexts. TMS is generally considered a safe and well-tolerated treatment, particularly for individuals with depression who have not responded well to other treatments like medication or therapy. Spravato is generally considered safe when used under the strict guidelines and supervision recommended by healthcare providers.

Patients will feel a tapping sensation on the scalp, right under the coil. The sensation is caused by the magnetic field stimulating the muscle and nerves beneath it, and therefore may cause mild discomfort to some. Alternatively, patients typically grow accustomed to the sensation, and over time, a vast majority consider TMS to be quite the comfortable treatment.

Often in the early stages of treatment, if a patient is responding well, they may notice physical changes, such as: - a boost in energy - positive changes in sleep patterns - a better appetite - improved cognition After a few weeks, you may notice overall mood changes, such as: - increased interest in activities - decreased sadness - decreased anxiousness - Friends and family, or coworkers may start to notice positive changes in demeanor

Our patient demographic is comprised of individuals who persistently experience moderate to severe depression symptoms, despite traditional intervention in the form of medication or therapy.

Choosing between Spravato and TMS depends on your specific condition, treatment/medical history, tolerance to potential side effects, and personal preference. At Oasis, you will be prescreened for any urgent risk factors during a free consultation, and then have the immediate opportunity for a clinical evaluation with our providers, who will help guide you in determining which treatment plan would be best for you.